Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 CAR-T Therapy for Refractory Autoimmune Diseases
NCT07059169Recruiting
- Start
- Aug 2025
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Open-label, single-arm trial of JY231 in systemic lupus erythematosus (SLE), Sjogren's syndrome, systemic sclerosis (SSc) and 2 more. Primary endpoints: Incidence of adverse events at Month 24 and Maximal Tolerated Dose. Started Aug 2025; status: recruiting.
02
Drugs
JY231
03
Conditions
systemic lupus erythematosus (SLE)Sjogren's syndromesystemic sclerosis (SSc)dermatomyositis (DM)anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on NCT07059169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07059169.